The only U.S. Food and Drug Administration (FDA)-approved drug for the treatment of ischemic stroke is the tissue-type plasminogen activator (tPA), but the narrow therapeutic time window within 4.5 hr greatly limits its application [7), leading to only about 5% of the patients benefiting from this treatment. This evidence concerns the gene PLAT and ischemic stroke.